T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2151
Dine Brands
DIN
$440M
| $822K | ﹤0.01% |
25,557
+1,010
| +4% | +$29.3K |
|
2152
Calumet Specialty Products
CLMT
$4.29B
| $821K | ﹤0.01% |
41,288
+3,688
| +10% | +$71K |
|
2153
Merchants Bancorp
MBIN
$2.54B
| $818K | ﹤0.01% |
24,014
+2,012
| +9% | +$66.1K |
|
2154
Compass Minerals
CMP
$1.1B
| $813K | ﹤0.01% |
41,359
-5,005
| -11% | -$92.6K |
|
2155
CryoPort
CYRX
$766M
| $813K | ﹤0.01% |
84,668
+17,088
| +25% | +$161K |
|
|
TRTX
2156
TPG RE Finance Trust
TRTX
$616M
| $813K | ﹤0.01% |
94,416
+3,589
| +4% | +$31.8K |
|
2157
RLJ Lodging Trust
RLJ
$1.67B
| $812K | ﹤0.01% |
108,942
-30,075
| -22% | -$219K |
|
|
KREF
2158
KKR Real Estate Finance Trust
KREF
$502M
| $809K | ﹤0.01% |
98,310
-398,356
| -80% | -$3.37M |
|
2159
Blue Owl Capital
OBDC
$5.87B
| $809K | ﹤0.01% |
65,017
-10,112
| -13% | -$129K |
|
|
UHT
2160
Universal Health Realty Income Trust
UHT
$573M
| $809K | ﹤0.01% |
20,621
+2,834
| +16% | +$110K |
|
2161
Novartis
NVS
$288B
| $803K | ﹤0.01% |
5,815
-425
| -7% | -$55.7K |
|
2162
Sinclair Inc
SBGI
$1.03B
| $802K | ﹤0.01% |
52,370
+8,449
| +19% | +$125K |
|
2163
Greenlight Captial
GLRE
$512M
| $801K | ﹤0.01% |
54,875
+16,307
| +42% | +$214K |
|
2164
AdaptHealth
AHCO
$760M
| $798K | ﹤0.01% |
80,059
-7,866
| -9% | -$75.1K |
|
2165
Coty
COTY
$2.42B
| $798K | ﹤0.01% |
258,822
+9,661
| +4% | +$35.1K |
|
2166
FIGS
FIGS
$2.47B
| $797K | ﹤0.01% |
70,113
+3,918
| +6% | +$36.7K |
|
|
CWEN.A
2167
DELISTED
Clearway Energy Class A
CWEN.A
| $792K | ﹤0.01% |
25,180
+1,067
| +4% | +$33.4K |
|
|
TDAY
2168
USA Today Co
TDAY
$1B
| $792K | ﹤0.01% |
153,786
+7,722
| +5% | +$36.3K |
|
2169
Clover Health Investments
CLOV
$2.38B
| $789K | ﹤0.01% |
335,524
-33,305
| -9% | -$91K |
|
2170
Ginkgo Bioworks
DNA
$488M
| $789K | ﹤0.01% |
94,873
+1,869
| +2% | +$20.1K |
|
2171
Oil States International
OIS
$526M
| $789K | ﹤0.01% |
116,426
+3,419
| +3% | +$22K |
|
2172
Shenandoah Telecom
SHEN
$744M
| $788K | ﹤0.01% |
68,126
+6,820
| +11% | +$80.7K |
|
|
AMWD
2173
DELISTED
American Woodmark
AMWD
| $787K | ﹤0.01% |
14,590
+2,655
| +22% | +$155K |
|
2174
Core Laboratories
CLB
$569M
| $785K | ﹤0.01% |
48,920
+5,578
| +13% | +$83K |
|
2175
Integra LifeSciences
IART
$1.42B
| $784K | ﹤0.01% |
63,075
+2,618
| +4% | +$34.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.